Delivering Innovative, Compassionate And Accessible Patient Care — Robert Stone, CEO — City of Hope & Dr. Marcel van den Brink, MD, PhD, President, City of Hope Comprehensive Cancer Center.

Robert Stone is the CEO of City of Hope (https://www.cityofhope.org/robert-stone), a premier cancer research and treatment center dedicated to innovation in biomedical science and the delivery of compassionate, world-class patient care. A seasoned health care executive, he has served in a number of strategic decision-making roles since he joined City of Hope in 1996, culminating with his appointment as president in 2012, CEO in 2014, and as the Helen and Morgan Chu Chief Executive Officer Distinguished Chair in 2021.

Mr. Stone has J.D., University of Chicago Law School, Chicago, IL.

Mr. Stone’s strategic acumen, empathy and visionary leadership have driven City of Hope’s rapid evolution.

As an independent institution dedicated to advancing the fight against cancer and diabetes, City of Hope is accelerating opportunities for high-impact discovery and ensuring that patients around the world have access to the most advanced therapies. Recent examples include a groundbreaking alliance in precision medicine with the Translational Genomics Research Institute (TGen), a leader in genomic analysis and bioinformatics; leadership in CAR T cell therapy research and therapy; and an innovative program to offer cancer support services to the employees of some of American’s largest employers, regardless of geography.

In the last few years, City of Hope has expanded access to its exceptional, patient-centered care, growing from a single site outside of Los Angeles to a clinical network spanning dozens of locations throughout the United States.

Mr. Stone recently was named Hospital CEO of the Year by the Los Angeles Business Journal and has been listed in the Los Angeles Business Journal’s Top 500 for five years. He was elected to the Healthcare Leadership Council, a nationwide policy advocacy organization, in 2017.

Dr. Marcel van den Brink, M.D., Ph.D.(https://www.cityofhope.org/marcel-van…), is President of City of Hope Cancer Center, main campus in Los Angeles, and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair, and is a globally recognized leader in the basic and translational science of bone marrow transplantation (BMT), the microbiome and cancer immunotherapy. His specialties include immune reconstitution and graft-versus-host disease — side effects many BMT patients experience — as well as the impact of the microbiome on immunotherapy for cancer.

Mike has over 15 years of experience in healthcare, including extensive experience designing and developing medical devices. MedCrypt, Inc.

On October 1, 2024, the Food and Drug Administration (FDA) marked a major milestone in medical device cybersecurity enforcement. This marks one year since the retracted Refuse to Accept (RTA) policy and the full implementation of the Protecting and Transforming Cyber Healthcare (PATCH) Act amendment to the Food, Drug & Cosmetic Act (FD&C). The FDA’s new requirements represent a fundamental shift in the regulatory landscape for medical device manufacturers (MDMs), as cybersecurity is now a non-negotiable element of device development and compliance.

The timing is not coincidental. In 2023, the FDA issued its final guidance entitled “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.” This outlined the detailed cybersecurity requirements and considerations that MDMs must address in their submissions, highlighting the security measures in place to gain regulatory approval. With these requirements, the FDA is taking a hard stance: Cybersecurity is a core consideration, with compliance being systematically enforced.

Imagine sitting down with an AI model for a spoken two-hour interview. A friendly voice guides you through a conversation that ranges from your childhood, your formative memories, and your career to your thoughts on immigration policy. Not long after, a virtual replica of you is able to embody your values and preferences with stunning accuracy.

That’s now possible, according to a new paper from a team including researchers from Stanford and Google DeepMind, which has been published on arXiv and has not yet been peer-reviewed.

SpaceX is preparing to launch the sixth Starship flight test. The window for the launch opens at 4 p.m. local time on Tuesday. The company has confirmed on its website, and X, that it is targeting a potential catch of the Super Heavy test vehicle, if flight parameters allow for it. SpaceX will also try to re-ignite a single Raptor engine in space to demonstrate deorbit capabilities.

Window Opens: November 19th at 4PM CST (22:00 UTC)
Window Closes: November 19th at 4:30PM CST (22:30 UTC)

Mission: Starship’s sixth fully integrated test flight.
Launch location: Orbital Launch Pad A, Starbase, Earth.
Target orbit: Trans-atmospheric.
Booster: Booster 13
Booster recovery: Orbital Launch Pad A launch tower arms.
Ship: Ship 31
Ship recovery: Will attempt soft splashdown on the Indian Ocean.
Rocket trajectory: Straight east over the Gulf of Mexico.
Stats:
· SpaceX’s 119th launch of the year and the 11th launch of the month.
· Starship’s 6th launch.
· 2nd Super Heavy recovery attempt.

Become a member of NASASpaceflight’s channel for exclusive discord access, fast turnaround clips, and other exclusive benefits. Your support helps us continue our 24/7 coverage.

If you are interested in using footage captured by this stream, please review our content use policy: https://www.nasaspaceflight.com/conte…

LDAPAABJRG2UMCU3.

Q: How might Trump’s administration impact AI development in the US? A: Trump aims to make America “first in AI” by dismantling Biden’s policy framework and reducing government regulation, potentially leading to skyrocketing growth in AI, cryptocurrencies, blockchain, Web3, and augmented reality.

Q: What’s J.D. Vance’s stance on AI development? A: Trump’s potential VP J.D. Vance supports open source AI and decentralized power, aiming to prevent large tech companies from steering regulation and allowing smaller innovators to compete.

Ionut Constantinescu, Tiago Pimentel, Ryan Cotterell, Alex Warstadt ETH Zurich 2024 https://arxiv.org/abs/2407.

Children are better at learning a…

We’ve detected that JavaScript is disabled in this browser. Please enable JavaScript or switch to a supported browser to continue using x.com. You can see a list of supported browsers in our Help Center.

Help Center

Terms of Service Privacy Policy Cookie Policy Imprint Ads info © 2024 X Corp.

Dimon was speaking at the Georgetown Psaros Center for Financial Markets and Policy’s annual Financial Markets Quality Conference when he was asked whether he had any advice for the students there.

“For most of you guys, turn off TikTok, Facebook. A total stupid waste of time,” Dimon said.

Reading widely and consuming history books, Dimon said, would be a far better use of their time.

The Salton Sea, California’s largest lake by surface area, is experiencing an increasing rate of shoreline retreat following a policy change that shifted more water from the Colorado River to San Diego, according to a newly published study. The resulting dried lakebed is creating more polluted dust from dried agricultural runoff that affects nearby communities, researchers said.

A two-line comment about “various compliance requirements” spurred questions about sanctions policy and procedure on the Linux kernel mailing list.

Protecting Human And Animal Health — Dr. Tristan Colonius, DVM — Chief Veterinary Officer & Deputy Director for Science Policy, Center for Veterinary Medicine (CVM), U.S. Food and Drug Administration (FDA)

Dr. Tristan Colonius, DVM is the Chief Veterinary Officer and Deputy Director for Science Policy at FDA’s Center for Veterinary Medicine (CVM — https://www.fda.gov/animal-veterinary).

Dr. Colonius previously worked in various positions at FDA, including as Deputy Chief of Staff to Commissioner Dr. Robert Califf and as an International Policy Analyst.

During his career at FDA, Dr. Colonius has been working on numerous initiatives including the Animal and Veterinary Innovation Agenda, One Health, Intentional Genomic Alterations in animals, and zootechnical animal feed substances (ZAFS) among many other programs at CVM.

Prior to joining FDA, Dr. Colonius held positions in the US Senate and US Department of Agriculture.

Dr. Colonius came to the Hill as an American Association for the Advancement of Science (AAAS) Science and Technology fellow in 2012 in Senator Kirsten Gillibrand’s (NY) office and worked to help pass the Agricultural Act of 2014 (the “Farm Bill”) renewal.

Dr. Colonius then went to work for Senator Diane Feinstein, first as a Legislative Assistant and then as her Deputy Legislative Director. While in Senator Feinstein’s office, Dr. Colonius worked on disaster preparedness, climate resiliency, emerging public health threats, homeland security, federal science policy, and animal welfare/conservation.

Dr. Colonius holds a BA in Political Science and Doctor of Veterinary Medicine from Louisiana State University, as well as a Master of Public Administration from the University of Illinois.